Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader in patient and physician friendly paradigm shifting antibiotic innovation. Its new mechanism antibiotics are designed to become the patient-friendly, new era standard-of-care, by working in harmony with the human microbiome to treat prospective patients suffering from infectious disease, initially focussing on Clostridioides difficile infections ("CDI") which is estimated to impact over 3 million patients worldwide annually. Commercialization of ridinilazole for the treatment of CDI is subject to regulatory approvals. The overriding objective of Summit Therapeutics is to create value for patients, hospital infectious disease care givers, community based infectious disease healthcare providers, as well as healthcare payors around the world. Currently, Summit's lead product candidate ridinilazole is engaged in two global phase III trials, Ri-CoDIFy 1 & 2, each enrolling 680 patients vs standard of care (Vancomycin) for the treatment of C. difficile infections.
Company profile
Ticker
SMMT
Exchange
Website
CEO
Robert W. Duggan
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Summit Corp plc, Summit Therapeutics plc
SEC CIK
Corporate docs
Subsidiaries
Summit (Oxford) Limited • Discuva Limited • Summit Therapeutics Sub Inc. • Summit Therapeutics Limited • Summit Corporation Limited • Summit (Wales) Limited • Summit (Cambridge) Limited • Summit Discovery 1 Limited • Summit Corporation • MuOx Limited ...
SMMT stock data
Latest filings (excl ownership)
8-K
Other Events
17 Mar 23
S-3
Shelf registration
17 Mar 23
10-K
2022 FY
Annual report
9 Mar 23
8-K
Results of Operations and Financial Condition
9 Mar 23
8-K
Summit Therapeutics Closes Fully-Subscribed
3 Mar 23
8-K
Summit Therapeutics’ Rights Offering Nearing Expiration Date
23 Feb 23
424B4
Prospectus supplement with pricing info
7 Feb 23
EFFECT
Notice of effectiveness
6 Feb 23
CORRESP
Correspondence with SEC
31 Jan 23
8-K
Other Events
30 Jan 23
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 648.61 mm | 648.61 mm | 648.61 mm | 648.61 mm | 648.61 mm | 648.61 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 6.77 mm | 6.01 mm | (no burn) | 3.47 mm |
| Cash used (since last report) | n/a | n/a | 20.14 mm | 17.88 mm | n/a | 10.32 mm |
| Cash remaining | n/a | n/a | 628.46 mm | 630.72 mm | n/a | 638.29 mm |
| Runway (months of cash) | n/a | n/a | 92.9 | 105.0 | n/a | 184.2 |
Institutional ownership, Q4 2022
1.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 59 |
| Opened positions | 25 |
| Closed positions | 7 |
| Increased positions | 16 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 29.96 bn |
| Total shares | 10.61 mm |
| Total puts | 834.80 k |
| Total calls | 646.64 k |
| Total put/call ratio | 1.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Zanganeh Maky | 2.57 mm | $0.00 |
| Baker Bros. Advisors | 2.00 mm | $8.50 bn |
| Vanguard | 1.44 mm | $6.14 bn |
| Marshall Wace | 622.87 k | $2.65 bn |
| BLK Blackrock | 534.66 k | $2.27 bn |
| Geode Capital Management | 471.67 k | $2.00 mm |
| Steward Partners Investment Advisory | 305.00 k | $1.30 bn |
| AWM Investment | 300.00 k | $1.28 bn |
| Two Sigma Investments | 286.20 k | $1.22 bn |
| Susquehanna International | 280.42 k | $1.19 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Mar 23 | Zanganeh Maky | Common Stock | Buy | Acquire P | Yes | No | 1.05 | 804,672 | 844.91 k | 1,178,529 |
| 8 Mar 23 | Zanganeh Maky | Common Stock | Buy | Acquire P | No | No | 1.05 | 15,973,743 | 16.77 mm | 23,395,269 |
| 8 Mar 23 | Zanganeh Maky | Common Stock | Buy | Acquire P | Yes | No | 1.05 | 6,748,629 | 7.09 mm | 9,884,095 |
| 8 Mar 23 | Zanganeh Maky | Common Stock | Buy | Acquire P | Yes | No | 1.05 | 16,778,415 | 17.62 mm | 24,573,798 |
| 7 Mar 23 | Ankur Dhingra | Common Stock | Buy | Acquire P | Yes | No | 1.05 | 196,362 | 206.18 k | 234,558 |
| 6 Mar 23 | Duggan Robert W | Common Stock | Buy | Acquire P | No | No | 1.05 | 376,489,880 | 395.31 mm | 552,354,161 |
News
Over $395M Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying
9 Mar 23
Macy's, Big Lots, Sprouts Farmers Market And Other Big Stocks Moving Higher On Thursday
2 Mar 23
Workday, AdaptHealth And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
28 Feb 23
12 Health Care Stocks Moving In Tuesday's Intraday Session
7 Feb 23
12 Health Care Stocks Moving In Friday's Intraday Session
3 Feb 23
Press releases
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
21 Mar 23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Summit Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
20 Mar 23
In The Queue: AcurX Pharmaceuticals Earnings…Here's What Investors Need To Know Before Thursday ($ACXP)
15 Mar 23
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022
9 Mar 23
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
3 Mar 23